A Safety Study of Intravenous Pro-Netupitant and Palonosetron Combination for the Prevention of Nausea and Vomiting
NCT02517021
Completed
NEPA-15-18 is a clinical study assessing safety of pro-netupitant and palonosetron, two antiemetic drugs, given with oral dexamethasone. The objective of the study is to evaluate if pro-netupitant and palonosetron are safe when administered to prevent nausea and vomiting after administration of repeated cycles of chemotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2018
Locations: Sarcoma Oncology Center, Santa Monica, California +1 locations
Conditions: Chemotherapy-Induced Nausea and Vomiting
Register for Updates
Mechanisms of Increased Androgen Production Among Women With Polycystic Ovary Syndrome
NCT00989781
Completed
Jeffrey Chang MD is conducting a research study to learn more about the increased male hormone levels, otherwise known as androgens, seen in women with polycystic ovary syndrome (PCOS). Women with PCOS have ovaries that are comprised of many cysts, or follicles. They also have irregular or absent menstrual periods and symptoms of increased male hormones, such as facial hair or acne. In each part of the study (except part 4 which is for PCOS women only) we will be comparing responses of PCOS wome... Read More
Gender:
FEMALE
Ages:
Between 18 years and 37 years
Trial Updated:
05/01/2018
Locations: UCSD Medical Center, San Diego, California
Conditions: Polycystic Ovary Syndrome
Register for Updates
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
NCT01478048
Completed
The purpose of the study is to determine whether the addition of Elotuzumab to Bortezomib/ Dexamethasone will prolong the time before myeloma worsens \[progression free survival (PFS)\].
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/20/2018
Locations: Compassionate Cancer Res Grp, Corona, California +8 locations
Conditions: Multiple Myeloma
Register for Updates
Treatment of Chronic Migraine Headaches.
NCT03220113
Unknown
The purpose of the study is assessment of the safety and efficacy of the De-Novo therapy in the treatment of craniofacial neuralgia and migraine headaches.This is an open-label study of simultaneous administration of combination of dexamethasone, lidocaine, and thiamine into the trigeminal nerve branches as well as greater and lesser occipital nerve bilaterally in one session. Patients who meet the exclusion and inclusion criteria are eligible for trial if they have experienced chronic migraine... Read More
Gender:
ALL
Ages:
Between 10 years and 90 years
Trial Updated:
04/02/2018
Locations: Corona Doctors Medical Clinics Inc, Corona, California
Conditions: Chronic Migraine Without Aura, Intractable, Migraine With Typical Aura, Migraine Disorders
Register for Updates
A Study of Ixazomib Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
NCT01217957
Completed
The purpose of Phase 1 of this study was to determine the safety, tolerability, maximum tolerated dose (MTD), and recommended Phase 2 dose (RP2D) of oral ixazomib administered in combination with lenalidomide and low-dose dexamethasone in participants with newly diagnosed multiple myeloma (NDMM). The purpose of Phase 2 of this study was to determine the overall response rate (ORR) and further evaluate the tolerability and toxicity of the combination of oral ixazomib, lenalidomide, and low-dose d... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/12/2018
Locations: Cedars Sinai Medical Center, Los Angeles, California
Conditions: Multiple Myeloma
Register for Updates
Effectiveness of Adventitial Dexamethasone in Peripheral Artery Disease
NCT01983449
Completed
To assess the safety and effectiveness of adventitial deposition of the Study Drug in reducing inflammation and restenosis in patients with clinical evidence of claudication or critical limb ischemia and an angiographically significant lesion in the superficial femoral and/or popliteal arteries. Study Drug and Dose: Dexamethasone Sodium Phosphate Injection, USP, 4 mg/ml, with dilute contrast (17%) administered to the adventitia in a dose of 1.6 mg per cm of desired vessel treatment length.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/06/2018
Locations: Cardiovascular Medical Group of Southern California / Cardiovascular Research Foundation, Beverly Hills, California +3 locations
Conditions: Peripheral Arterial Diseases
Register for Updates
Safety, Efficacy, and Pharmacodynamics of a 60-Minute Infusion of Carfilzomib for Progressive Multiple Myeloma
NCT01792102
Unknown
This is a Phase 1/2, multicenter, open label, dose-escalation, nonrandomized study to evaluate the safety, pharmacodynamics, and efficacy of a 60-minute infusion of carfilzomib for patients with progressive multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/01/2018
Locations: James R. Berenson M.D. Inc., West Hollywood, California
Conditions: Multiple Myeloma
Register for Updates
Efficacy of Perifosine Alone and in Combination With Dexamethasone for Patients With Multiple Myeloma
NCT00375791
Completed
This is a phase 2 study of perifosine in patients with multiple myeloma. Patients will receive perifosine 150 mg at bedtime (qhs) daily. Patients will be assessed by serum and/or urine-electrophoresis at least every 3 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/27/2018
Locations: Investigative Site, Berkeley, California +1 locations
Conditions: Multiple Myeloma
Register for Updates
A Phase 1 Study Evaluating CB-5083 in Subjects With Lymphoid Hematological Malignancies
NCT02223598
Terminated
The purpose of this study is to determine the safety, tolerability, dose limiting toxicities, and maximum tolerated dose of CB-5083 in subjects with lymphoid hematological malignancies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/23/2018
Locations: City of Hope National Medical Center, Duarte, California +1 locations
Conditions: Lymphoid Hematological Malignancies, Relapsed and Refractory Multiple Myeloma
Register for Updates
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
NCT01002248
Terminated
This is a randomized Phase III study to evaluate the efficacy and safety of perifosine when added to the combination of bortezomib and dexamethasone in multiple myeloma patients who have relapsed on a prior bortezomib treatment regimen.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/06/2018
Locations: Not set, La Verne, California +2 locations
Conditions: Multiple Myeloma
Register for Updates
A Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor (Ruxolitinib; INBC018424) in Patients With Multiple Myeloma
NCT00639002
Completed
The purpose of this study was to determine clinical efficacy and safety of ruxolitinib (INCB018424), a small molecule Janus kinase 2 (JAK2)-inhibitor, in patients with refractory or relapsed multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/15/2018
Locations: Not set, Highland, California
Conditions: Multiple Myeloma
Register for Updates
Dexamethasone Infusion to the Adventitia to Enhance Clinical Efficacy After Femoropopliteal Revascularization
NCT01507558
Completed
The purpose of this study is to test if dexamethasone, an anti-inflammatory medication approved by the US Food and Drug Administration (FDA), can be injected safely into the tissue around the blood vessel wall at the time of an angioplasty or atherectomy.
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
01/04/2018
Locations: San Francisco VA Medical Center, San Francisco, California +1 locations
Conditions: Peripheral Arterial Disease
Register for Updates